Carregant...
Electrophysiological Basis for the Antiarrhythmic Actions of Ranolazine
Ranolazine is an FDA-approved anti-anginal agent. Experimental and clinical studies have shown that ranolazine has anti-arrhythmic effects in both ventricles and atria. In the ventricles, ranolazine can suppress arrhythmias associated with acute coronary syndrome, long QT, heart failure, ischemia, a...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3131428/ https://ncbi.nlm.nih.gov/pubmed/21421082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hrthm.2011.03.045 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|